Viral Vector News and Research

RSS

Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.

Novel approach: intranasal vaccination strategy targets Omicron COVID-19 variants

Researchers tested the efficacy of a two to three-dose intranasal (IN) regimen of the NDV-HXP-S vaccine.

14 Jul 2023

Advances in influenza research

This interview with Dr. Mohammad S Safiarian, Associate Product Manager at Sino Biological, discusses the advances in influenza research and how effective vaccines are developed.

From Sino Biological Inc. 30 Jun 2023

Cell and gene therapy CDMO Andelyn Biosciences celebrates over 20 years of leadership and innovation with opening of new 180,000 square foot manufacturing headquarters

Andelyn Biosciences, a pioneer in the development and manufacturing of cell and gene therapies, today formally inaugurates its new manufacturing headquarters, the Andelyn Corporate Center (ACC), located in the Innovation District in Columbus, Ohio.

From Andelyn Biosciences 23 Jun 2023

Catalent expands OneBio® suite for integrated development, manufacturing and supply across biologic modalities

Catalen today announced that it has expanded its integrated development, manufacturing and supply solution, OneBio® Suite, across a range of biologic modalities, including antibody and recombinant proteins, cell and gene therapies, and mRNA.

From Catalent 16 Jun 2023

Researchers review the principles of universal vaccine development for key pandemic potential viruses

A recent review addressed the efforts to develop universal vaccines for viruses at family and genus levels.

16 Jun 2023

Charles River Laboratories Launches Off-the-Shelf Lentiviral Vector Packaging Plasmids

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf lentiviral vector (LVV) packaging plasmids, providing a streamlined solution to the challenges associated with plasmid sourcing in cell and gene therapies.

From Charles River Laboratories, Inc. 13 Jun 2023

Experimental decoy provides long-term protection from SARS-Cov-2 infection

An experimental "decoy" provided long-term protection from infection by the pandemic virus in mice, a new study finds.

30 May 2023

Nemours Children's Health selected to conduct first gene therapy clinical trial for Morquio A syndrome

As part of the Foundation for the National Institutes of Health Accelerating Medicines Partnership Bespoke Gene Therapy Consortium, Nemours Children's Health has been chosen to conduct a first-of-its-kind gene therapy clinical trial for Morquio A syndrome.

16 May 2023

Vector Biolabs expands viral vector manufacturing capacity and adds to QC capabilities

Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing demand.

12 May 2023

New technology can deliver gene therapy directly to the lung

Scientists at UMass Chan Medical School have developed a technology to deliver gene therapy directly to lung tissue through intranasal administration, a development that could potentially create a new class of treatments for lung disease.

2 May 2023

Researchers identify regions of the viral envelope of simian foamy viruses targeted by neutralizing antibodies

A recent study characterized epitopes recognized by neutralizing antibodies from individuals infected with simian foamy virus.

26 Apr 2023

Gene therapy approach can decrease intraocular pressure in pre-clinical models of glaucoma

Scientists at Trinity College Dublin today announced a significant development towards a new therapeutic treatment of glaucoma.

19 Apr 2023

Overcoming challenges in flavivirus vaccine development: Exploring modern vaccine types for Dengue, Zika, and beyond

Researchers discuss the challenges impeding the development of vaccines against flaviviruses.

4 Apr 2023

Tetravalent COVID vaccine provides broad antibody responses against SARS-CoV-2 variants in animal model

In a recent study posted to the bioRxiv* preprint server, researchers in Italy and the United States evaluated the efficacy and immunogenicity of an adjuvanted tetravalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit 1 (S1) COVID-19 vaccine.

21 Mar 2023

How effective are monovalent mRNA COVID-19 vaccine booster doses against Omicron-associated severe outcomes among adults?

Researchers from Canada investigated the efficacy of booster doses of the monovalent mRNA COVID-19 vaccine in preventing hospitalization and death during the dominance of the SARS-CoV-2 Omicron variant.

10 Mar 2023

Exploring COVID-19 immunization speed and timing in Africa

A new BMC Medicine study retrospectively analyzed the impact of COVID-19 vaccination timing and speed on the virus transmission in 27 African countries, based on a combined epidemiological and economic modeling approach. The authors aimed to inform future decisions about vaccine roll-out and investment.

10 Mar 2023

Meta-analysis on COVID-19 vaccine effectiveness in association with antibody titers

Researchers performed a meta-analysis analyzing randomized controlled trials (RCTs) that evaluated the effectiveness of coronavirus disease 2019 (COVID-19) vaccines, and the dose-response association of humoral responses with vaccine effectiveness.

6 Mar 2023

Simple blood tests for telomeric protein could provide a valuable screen for certain cancers

Once thought incapable of encoding proteins due to their simple monotonous repetitions of DNA, tiny telomeres at the tips of our chromosomes seem to hold a potent biological function that's potentially relevant to our understanding of cancer and aging.

21 Feb 2023

COVID-19 vaccination associated with fewer heart attacks, strokes, and other cardiovascular issues

Analyzing the most extensive datasets in the United States, researchers from the Icahn School of Medicine at Mount Sinai have revealed that vaccination against COVID-19 is associated with fewer heart attacks, strokes, and other cardiovascular issues among people who were infected with SARS-CoV-2, the virus that causes COVID-19.

20 Feb 2023

CHLA researchers receive funding to support studies into diffuse intrinsic pontine glioma

Researchers at Children's Hospital Los Angeles have received a nearly $1 million K08 grant from the National Institutes of Health (NIH)-; as well as funding from the U.S. Department of Defense-;to support studies into diffuse intrinsic pontine glioma (DIPG), a childhood brain tumor with a 0% survival rate.

16 Feb 2023